Abstract: The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.
Type:
Grant
Filed:
June 8, 2009
Date of Patent:
March 27, 2012
Assignee:
XenoPort, Inc.
Inventors:
Mark A. Gallop, Jia-Ning Xiang, Fenmei Yao, Laxminarayan Bhat, Cindy X. Zhou
Abstract: Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome.
Abstract: The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
Type:
Application
Filed:
October 14, 2011
Publication date:
February 9, 2012
Applicant:
XenoPort, Inc.
Inventors:
Mark A. Gallop, Kenneth C. Cundy, Cindy X. Zhou, Fenmei Yao, Jia-Ning Xiang, Ian R. Ollman, Fayang G. Qiu
Abstract: Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down's syndrome and other forms of mental retardation, and/or autism comprising administering a GABAB agonist prodrug to a subject suffering therefrom. The GABAB agonist prodrugs can be compounds of Formula (I), (II) or (III) as disclosed herein.
Type:
Application
Filed:
July 15, 2011
Publication date:
January 19, 2012
Applicant:
XENOPORT, INC.
Inventors:
David J. Wustrow, Peter A. Virsik, Mark A. Gallop
Abstract: Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
Type:
Application
Filed:
August 11, 2011
Publication date:
January 12, 2012
Applicant:
XENOPORT, INC.
Inventors:
Mark A. Gallop, Xuedong Dai, Randall A. Scheuerman, Stephen P. Raillard, Suresh K. Manthati, Fenmei Yao, Thu Phan, Maria Ludwikow, Ge Peng, Seema Bhat
Abstract: Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down's syndrome and/or autism, comprising administering a prodrug of acamprosate to a subject suffering therefrom, wherein, in certain embodiments, the acamprosate prodrugs comprise compounds of Formula (I).
Type:
Application
Filed:
May 27, 2011
Publication date:
December 1, 2011
Applicant:
XENOPORT, INC.
Inventors:
Bernd Jandeleit, Mark A. Gallop, Peter A. Virsik, David J. Wustrow
Abstract: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.
Type:
Grant
Filed:
October 2, 2009
Date of Patent:
November 29, 2011
Assignee:
XenoPort, Inc.
Inventors:
Feng Xu, Mark A. Gallop, Vivek Sasikumar, Usha Dilip
Abstract: The present disclosure provides 2?-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2?-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2?-C-methyl-ribofuranosyl cytidine prodrugs, and methods of using 2?-C-methyl-ribofuranosyl cytidine prodrugs and pharmaceutical compositions thereof to treat viral diseases such as hepatitis C.
Abstract: The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
Type:
Grant
Filed:
April 6, 2005
Date of Patent:
November 1, 2011
Assignee:
XenoPort, Inc.
Inventors:
Mark A. Gallop, Kenneth C. Cundy, Cindy X. Zhou, Fenmei Yao, Jia-Ning Xiang
Abstract: A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug are provided.
Type:
Application
Filed:
December 7, 2010
Publication date:
September 15, 2011
Applicant:
XenoPort, Inc.
Inventors:
Fenmei Yao, Mark A. Gallop, Ronald W. Barrett, Peter A. Virsik
Abstract: Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.
Abstract: Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence is disclosed.
Abstract: Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
Type:
Grant
Filed:
February 20, 2009
Date of Patent:
August 23, 2011
Assignee:
XenoPort, Inc.
Inventors:
Mark A. Gallop, Xuedong Dai, Randall A. Scheuerman, Stephen P. Raillard, Suresh K. Manthati, Fenmei Yao, Thu Phan, Maria J. Ludwikow, Ge Peng, Seema Bhat
Abstract: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.
Type:
Application
Filed:
April 27, 2011
Publication date:
August 18, 2011
Applicant:
XenoPort, Inc.
Inventors:
Jia-Ning XIANG, Mark A. Gallop, Cindy X. Zhou, Mark Nguyen, Xuedong Dai, Jianhua Li, Kenneth C. Cundy, Nelson L. Jumbe
Abstract: Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.
Type:
Grant
Filed:
September 5, 2008
Date of Patent:
August 9, 2011
Assignee:
XenoPort, Inc.
Inventors:
Bernd Jandeleit, Yunxiao Li, Mark A. Gallop, Noa Zerangue, Peter A. Virsik, Wolf-Nicolas Fischer
Abstract: The present disclosure relates to methods of synthesizing N-hydroxysuccinimidyl-carbonate intermediates from the corresponding sulfones useful in the preparation of 1-(acyloxy)-alkyl carbamate prodrugs.
Type:
Grant
Filed:
August 7, 2009
Date of Patent:
August 2, 2011
Assignee:
XenoPort, Inc.
Inventors:
Stephen P. Raillard, Suresh K. Manthati, Peng Liu, Qunying Dai, Hao Yin
Abstract: (2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.